A triple-combination product for the treatment of moderate-to-severe melasma shows a clinical success rate double that of previously used compounds. The once-daily regimen containing hydroquinone, a depigmenting agent (4.0%), tretinoin, a retinoid (0.05%), and fluocinolone acetonide (Tri-Luma), a low-potency steroid (0.01%), has a favorable safety profile and is well tolerated by patients. Tri-Luma received US Food and Drug Administration marketing approval earlier this year.
“Tri-Luma is a welcome addition to the dermatology marketplace,” Pearl Grimes, MD, associate clinical professor of dermatology at the University of California at Los Angeles, tells WebMD. “As a therapeutic material for melasma, it requires no extemporaneous compounding.”
Tri-Luma is the first triple therapy indicated for the short-term treatment of moderate-to-severe melasma of the face in the presence of measures for sun avoidance, including the use of sunscreen.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!